Clinical evaluation of tobramycin in urinary tract infections.
Twenty-one patients with urinary tract infections due to Pseudomonas and coli-form bacilli were treated with 80-120 mg of tobramycin per day in two daily doses. Of these patients, 14 (67%) were cured, one improved, three (14%) showed no improvement, and three (14%) showed a substitution of the original pathogen by another organism. Urine cultures demonstrated rapid sterilization in the cases in which patients responsed well, and long-term sterility persisted in at least 50% of the subjects.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D014031:Tobramycin